Patients receiving BTKis often require concomitant antithrombotic therapy for atrial fibrillation (AF), ischemic heart disease, or venous thromboembolism—conditions that may themselves be precipitated or exacerbated by BTK inhibition (17). Here, BTK is linked to atrial fibrillation.